Apyx Medical reported Q2 2026 revenue of $13.9 million, up 22.1% year over year, as Surgical Aesthetics sales climbed 28.1% to $12.4 million. The GAAP net loss attributable to stockholders narrowed to $3.2 million, and the non-GAAP adjusted EBITDA loss improved to $0.7 million from $2.0 million. Gross margin rose to 63.9%, but operating cash use increased to $3.5 million on working-capital changes. The company reaffirmed FY2026 revenue guidance of $59.0 million to $60.0 million, led by continued Surgical Aesthetics growth.